ATRC - AtriCure, Inc.
| Previous Close | 29.42 |
| Open | 29.19 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 800 |
| Day's Range | 28.94 - 29.60 |
| 52 Week Range | 23.56 - 36.49 |
| Volume | 109,773 |
| Avg. Volume | 263,787 |
| Market Cap | 1.136B |
| Beta (3Y Monthly) | 0.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.47 |
| Earnings Date | Jul 30, 2019 - Aug 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 36.71 |
- CNBC•16 days ago
These stocks have 'underappreciated' stories, Wall Street analysts say
Analysts named Corning, Target, Costco, AtriCure, and Coupa Software as having "underappreciated" stock stories. "Increased control over product supply is an underappreciated part of the Costco investment story," Baird analyst Peter Benedict said.
- Insider Monkey•19 days ago
Hedge Funds Have Never Been More Bullish On AtriCure Inc. (ATRC)
The government requires hedge funds and wealthy investors that crossed the $100 million equity holdings threshold are required to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings level the playing field for ordinary investors. The latest round of 13F filings disclosed the […]
- Thomson Reuters StreetEvents•19 days ago
Edited Transcript of ATRC earnings conference call or presentation 25-Apr-19 8:30pm GMT
Q1 2019 AtriCure Inc Earnings Call
Motley Fool•25 days agoAtriCure Inc (ATRC) Q1 2019 Earnings Call Transcript
ATRC earnings call for the period ending March 31, 2019.
- Associated Press•26 days ago
AtriCure: 1Q Earnings Snapshot
The Mason, Ohio-based company said it had a loss of 15 cents per share. Losses, adjusted for non-recurring gains, came to 20 cents per share. The results beat Wall Street expectations. The average estimate ...
- Business Wire•26 days ago
AtriCure Reports First Quarter 2019 Financial Results
MASON, Ohio-- -- Worldwide revenue of $54.0 million – an increase of 14.8% year over year U.S. revenue of $43.0 million – an increase of 11.9% year over year International revenue of $11.0 million – an increase of 28.1% year over year AtriCure, Inc. , a leading innovator in treatments for atrial fibrillation and left atrial appendage management, today announced first quarter 2019 financial results. ...
- ACCESSWIRE•26 days ago
AtriCure, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / April 25, 2019 / AtriCure, Inc. (NASDAQ: ATRC ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on April 25, 2019 at 4:30 PM Eastern ...
- Business Wire•28 days ago
AtriCure Announces First Patient Enrollment in the DEEP IDE Trial Restart
AtriCure, Inc. (ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced the restart of the Dual Epicardial and Endocardial Procedure (DEEP) clinical trial (NCT02393885). Following approval by the FDA to restart the trial and enroll an additional 40 subjects, which was granted in December 2018, the first patient was treated by a team led by Professor Mark La Meir and Professor Carlo de Asmundis at Universitair Ziekenhuis Brussels, Belgium. The DEEP trial is a prospective, multicenter, single arm, investigational device exempt (IDE) study to evaluate the safety and efficacy of the DEEP procedure in treating persistent and long-standing persistent atrial fibrillation.
- Zacks•last month
AtriCure (ATRC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire•2 months ago
AtriCure to Announce First Quarter 2019 Financial Results
AtriCure, Inc. , a leading innovator in treatments for atrial fibrillation and left atrial appendage management, today announced that it will release its first quarter 2019 financial results on Thursday, April 25, 2019.
- Business Wire•2 months ago
AtriCure to Present at the Needham & Company’s 18th Annual Healthcare Conference
AtriCure, Inc. , a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, today announced that it will present at the Needham & Company’s 18th Annual Healthcare Conference in New York on Wednesday, April 10, 2019.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of ATRC earnings conference call or presentation 28-Feb-19 9:30pm GMT
Q4 2018 AtriCure Inc Earnings Call
- GlobeNewswire•3 months ago
Factors of Influence in 2019, Key Indicators and Opportunity within Expedia Group, Lumentum, Patterson Companies, Allscripts Healthcare Solutions, AtriCure, and Biohaven Pharmaceutical Holding — New Research Emphasizes Economic Growth
NEW YORK, March 05, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GuruFocus.com•3 months ago
AtriCure Inc (ATRC) Files 10-K for the Fiscal Year Ended on December 31, 2018
AtriCure Inc (NASDAQ:ATRC) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.
Motley Fool•3 months agoAtriCure Inc (ATRC) Q4 2018 Earnings Conference Call Transcript
ATRC earnings call for the period ending December 31, 2018.
- Business Wire•3 months ago
AtriCure Reports Fourth Quarter and Full Year 2018 Financial Results
MASON, Ohio-- -- 2018 Worldwide revenue of $201.6 million – an increase of 15.4% year over year 2018 U.S. revenue of $162.1 million – an increase of 17.2% year over year 2018 International revenue of $39.5 million – an increase of 8.7% year over year AtriCure, Inc. , a leading innovator in treatments for atrial fibrillation and related conditions, today announced fourth quarter and full year 2018 financial ...
- American City Business Journals•3 months ago
Mason firm to add 100-plus jobs in $15M expansion
Mason City Council voted on Monday to provide $3.6 million in incentives to a local firm planning to add more than 100 jobs as part of a $15 million headquarters expansion.
- Zacks•3 months ago
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire•3 months ago
AtriCure Announces The Society of Thoracic Surgeons Has Endorsed the Company’s Advanced Ablation Courses in the United States
AtriCure, Inc. (ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced that The Society of Thoracic Surgeons (STS) has endorsed its Advanced Ablation course for both physicians and fellows. The course provides surgeons and other medical professionals with a comprehensive overview of the treatment of Afib during cardiac surgery. Founded in 1964, STS is a not-for-profit organization representing more than 7,500 cardiothoracic surgeons, researchers, and allied health care professionals worldwide who are dedicated to ensuring the best possible outcomes for surgeries of the heart, lungs, and esophagus, as well as other procedures within the chest.
- Business Wire•3 months ago
AtriCure Announces Launch of the cryoICE® cryoSPHERE™ Probe
cryoSPHERE probe launched in United States, designed exclusively for post-operative pain block
- Business Wire•3 months ago
AtriCure Announces the First Patient Enrolled in the ICE-AFIB™ Clinical Trial
AtriCure, Inc. (ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced the first patient was treated in the ICE-AFIB™ trial (NCT03732794). Following Investigational Device Exemption (IDE) approval by the FDA, the first patient was treated by Dr. Niv Ad, at Washington Adventist Hospital in Takoma Park, Maryland.
- Business Wire•3 months ago
AtriCure to Announce Fourth Quarter and Full Year 2018 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2018 financial results on Thursday, February 28, 2019. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, February 28, 2019 to discuss its fourth quarter and full year 2018 financial results. The call may be accessed through an operator by calling (844) 884-9951 for domestic callers and (661) 378-9661 for international callers using conference ID number 5981957.
- Zacks•4 months ago
AtriCure (ATRC) Upgraded to Strong Buy: Here's What You Should Know
AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- GlobeNewswire•4 months ago
Recent Analysis Shows Textron, Occidental Petroleum, AtriCure, Chegg, KBR, and V.F. Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Jan. 28, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Simply Wall St.•4 months ago
Who Has Been Buying AtriCure, Inc. (NASDAQ:ATRC) Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
